{"drugs":["Entyvio","Vedolizumab"],"mono":{"0":{"id":"930961-s-0","title":"Generic Names","mono":"Vedolizumab"},"1":{"id":"930961-s-1","title":"Dosing and Indications","sub":{"0":{"id":"930961-s-1-4","title":"Adult Dosing","mono":"<ul><li>ensure patient is up to date with all immunizations prior to initiating therapy<\/li><li><b>Crohn's disease (Moderate to Severe), Inadequate or intolerant to tumor necrosis factor (TNF) blocker, immunomodulator, or corticosteroids, or lost response to TNF or immunomodulator, or demonstrated dependence on corticosteroids:<\/b> 300 mg IV infusion over 30 minutes on day 1, repeat dose at 2 weeks, 6 weeks, and then every 8 weeks thereafter<\/li><li><b>Crohn's disease (Moderate to Severe), Inadequate or intolerant to tumor necrosis factor (TNF) blocker, immunomodulator, or corticosteroids, or lost response to TNF or immunomodulator, or demonstrated dependence on corticosteroids:<\/b> discontinue use if no evidence of efficacy by week 14<\/li><li><b>Ulcerative colitis (Moderate to Severe), Inadequate or intolerant to tumor necrosis factor (TNF) blocker, immunomodulator, or corticosteroids, or lost response to TNF or immunomodulator, or demonstrated dependence on corticosteroids:<\/b> 300 mg IV infusion over 30 minutes on day 1, repeat dose at 2 weeks, 6 weeks, and then every 8 weeks thereafter<\/li><li><b>Ulcerative colitis (Moderate to Severe), Inadequate or intolerant to tumor necrosis factor (TNF) blocker, immunomodulator, or corticosteroids, or lost response to TNF or immunomodulator, or demonstrated dependence on corticosteroids:<\/b> discontinue use if no evidence of efficacy by week 14<\/li><\/ul>"},"1":{"id":"930961-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in pediatric patients "},"3":{"id":"930961-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Crohn's disease (Moderate to Severe), Inadequate or intolerant to tumor necrosis factor (TNF) blocker, immunomodulator, or corticosteroids, or lost response to TNF or immunomodulator, or demonstrated dependence on corticosteroids<\/li><li>Ulcerative colitis (Moderate to Severe), Inadequate or intolerant to tumor necrosis factor (TNF) blocker, immunomodulator, or corticosteroids, or lost response to TNF or immunomodulator, or demonstrated dependence on corticosteroids<\/li><\/ul>"}}},"3":{"id":"930961-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930961-s-3-9","title":"Contraindications","mono":"hypersensitivity reaction, severe or serious, to vedolizumab or any of its excipients <br\/>"},{"id":"930961-s-3-10","title":"Precautions","mono":"<ul><li>Hepatic:<\/li><li>-- liver injury, which may be fatal or require transplant, may occur; discontinue use if jaundice or other evidence develops<\/li><li>Immunologic:<\/li><li>-- active, severe infection; use not recommended<\/li><li>-- history of recurrent severe infections; consider use cautiously<\/li><li>-- infusion and hypersensitivity reactions, including anaphylaxis, have been reported; monitoring recommended; discontinue use and institute appropriate therapy<\/li><li>-- serious infections have been reported, including cytomegaloviral colitis, sepsis, TB, and fatalities; consider TB screening; withhold treatment until resolution<\/li><li>Neurologic:<\/li><li>-- progressive multifocal leukoencephalopathy (PML) may occur, especially in immunocompromised patients; monitoring recommended; withhold dosing if PML is suspected and discontinue permanently if confirmed<\/li><li>Concomitant use:<\/li><li>-- live vaccines; ensure current immunizations are up to date prior to therapy initiation; use only if benefit outweighs risk<\/li><li>-- natalizumab and tumor necrosis factor blockers; avoid use<\/li><\/ul>"},{"id":"930961-s-3-11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"930961-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"930961-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Nausea (9%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (12%)<\/li><li><b>Neurologic:<\/b>Headache (12%)<\/li><li><b>Respiratory:<\/b>Nasopharyngitis (13%), Upper respiratory infection (7%)<\/li><li><b>Other:<\/b>Fatigue (6%), Fever (9%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hepatic:<\/b>Aminotransferase abnormal, Increased (less than 2%), Hepatitis, Serum bilirubin raised<\/li><li><b>Immunologic:<\/b>Anaphylaxis (0.07%), Hypersensitivity reaction, Infusion reaction (4%)<\/li><li><b>Neurologic:<\/b>Progressive multifocal leukoencephalopathy<\/li><li><b>Respiratory:<\/b>Tuberculosis<\/li><li><b>Other:<\/b>Cancer (0.4%), Infectious disease, Sepsis (0.03%)<\/li><\/ul>"},"6":{"id":"930961-s-6","title":"Drug Name Info","sub":{"0":{"id":"930961-s-6-17","title":"US Trade Names","mono":"Entyvio<br\/>"},"2":{"id":"930961-s-6-19","title":"Class","mono":"Monoclonal Antibody<br\/>"},"3":{"id":"930961-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930961-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930961-s-7","title":"Mechanism Of Action","mono":"Vedolizumab reduces chronically inflamed gastrointestinal parenchymal tissue associated with ulcerative colitis and Crohn disease by binding specifically to the alpha-4-beta-7-integrin receptor and blocking its interaction with mucosal addressin cell adhesion molecule-1. This inhibits the movement of memory T-lymphocytes across the endothelium into inflamed gastrointestinal tissue.<br\/>"},"8":{"id":"930961-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"930961-s-8-24","title":"Distribution","mono":"Vd: 5 L <br\/>"},"3":{"id":"930961-s-8-26","title":"Excretion","mono":"Total body clearance: 0.157 L\/day (linear pathway) <br\/>"},"4":{"id":"930961-s-8-27","title":"Elimination Half Life","mono":"25 days <br\/>"}}},"9":{"id":"930961-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>reconstitute with 4.8 mL sterile water for injection<\/li><li>gently swirl to dissolve; do not invert or shake vigorously<\/li><li>allow reconstituted solution to rest at room temperature for up to 20 minutes to settle any foam; do not use solution if not fully dissolved in 30 minutes<\/li><li>gently invert vial 3 times prior to withdrawing required dose<\/li><li>dilute dose in 250 mL NS; do not add other drugs to the admixture<\/li><li>use infusion solution as soon as possible after preparation, or store for up to 4 hours between 2 and 8 degrees C (36 to 46 degrees F)<\/li><li>infuse over 30 minutes and flush line with 30 mL NS upon completion<\/li><li>do not administer as IV push or bolus<\/li><\/ul>"},"10":{"id":"930961-s-10","title":"Monitoring","mono":"<ul><li>evidence of clinical benefit of treatment of ulcerative colitis or Crohn disease by week 14<\/li><li>TB screening<\/li><li>hypersensitivity reactions during and until the completion of the infusion; onset of infusion and hypersensitivity reactions may vary from during or immediately following the infusion, to several hours afterwards<\/li><li>signs and symptoms of progressive multifocal leukoencephalopathy, including new onset or worsening of neurological function; diverse signs and symptoms typically progress over days to weeks but severe disability may progress over weeks or months<\/li><\/ul>"},"11":{"id":"930961-s-11","title":"How Supplied","mono":"<b>Entyvio<\/b><br\/>Intravenous Powder for Solution: 300 MG<br\/>"},"13":{"id":"930961-s-13","title":"Clinical Teaching","mono":"<ul><li>Tell patient to immediately report symptoms of hypersensitivity reaction during or after infusion.<\/li><li>Instruct patient to report symptoms of infection.<\/li><li>Counsel patient to immediately report new or worsening neurological symptoms indicative of progressive multifocal leukoencephalopathy (eg, progressive unilateral weakness, visual disturbances, changes in cognition and memory associated with confusion and personality changes).<\/li><li>Direct patient to promptly report symptoms of hepatic injury.<\/li><li>Side effects may include nasopharyngitis, cough, bronchitis, sinusitis, oropharyngeal pain, nausea, headache, pyrexia, upper respiratory tract infection, influenza, fatigue, arthralgia, back or limb pain, rash, or pruritus.<\/li><\/ul>"}}}